Number of Shares and Voting Rights of ADOCIA as of April 30th, 2023
16 Maio 2023 - 1:00PM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA (Paris:ADOC), a French société anonyme (corporation),
115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 –
ADOC) a clinical stage biopharmaceutical company focused on
treatment of diabetes, obesity and metabolic diseases with
innovative formulations of approved proteins, releases its total
number of outstanding shares as well as its voting rights as of
April 30th, 2023.
Month
Date
Total number of outstanding
shares
Total number of theoretical
voting rights (1)
Total number of exercisable
voting rights (2)
April
04/30/2023
8,970,451
11,741,836
11,699,203
*including 15,565 new shares resulting from the conversion of
40,000 bonds convertible into shares (OC 1124) issued by the
Company on December 1, 2022. The main characteristics are described
in the press releases of the days of issue.
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement.
About Adocia
Adocia is a biotechnology company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity. The company has a broad
portfolio of drug candidates based on three proprietary technology
platforms:
1) The BioChaperone® technology for the development of new
generation insulins and products combining insulins with other
classes of hormones; 2) AdOral®, an oral peptide delivery
technology; 3) AdoShell® Islets, an immunoprotective biomaterial
for cell transplantation with a first application in pancreatic
cells transplantation for patients with "brittle" diabetes.
Adocia holds more than 25 patent families.
Based in Lyon, the company has 105 employees. Adocia is listed
on the EuronextTM Paris market (Euronext: ADOC; ISIN:
FR0011184241).
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those which are set forth
in the “Risk Factors” section of the universal registration
document that was filed with the French Autorité des marchés
financiers on April 26, 2023 (a copy of which is available at
www.adocia.com), in particular uncertainties that are linked to
research and development, future clinical data, analyses, and the
evolution of the economic context, the financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not considered as material by Adocia as of this
day. The occurrence of all or part of such risks could cause that
actual results, financial conditions, performances, or achievements
of Adocia be materially different from those mentioned in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230516005842/en/
Adocia
Olivier Soula CEO contactinvestisseurs@adocia.com
Tel : +33 4 72 610 610 www.adocia.com
Adocia Press and Investors Relations
Ulysse Communication Pierre-Louis Germain Margaux
Puech Pays d’Alissac Bruno Arabian
adocia@ulysse-communication.com +33 (0)6 64 79 97 51
Edoc Acquisition (NASDAQ:ADOC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Edoc Acquisition (NASDAQ:ADOC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024